Report: Multiple Suitors - Including BMS - Vied for Acceleron’s Attention

Last month, Merck and Acceleron struck an $11.5 billion merger agreement, but before those two companies opted to walk down the aisle, rare-disease-focused Acceleron Pharma was wooed by multiple suitors, including pharma giant Bristol Myers Squibb.